Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 23714488)

1.
2.

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Opin Biol Ther. 2014 Jan;14(1):7-10. doi: 10.1517/14712598.2013.840582. Epub 2013 Sep 27.

PMID:
24074253
3.

Treating patients with metastatic castration-resistant prostate cancer: a comprehensive review of available therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Jul 18. pii: S0022-5347(15)04423-7. doi: 10.1016/j.juro.2015.06.106. [Epub ahead of print] Review.

PMID:
26196735
4.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948
5.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
6.

Sequencing systemic therapies in metastatic castration-resistant prostate cancer.

Liu JJ, Zhang J.

Cancer Control. 2013 Jul;20(3):181-7. Review.

7.

Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.

Saad F, Miller K.

Urol Oncol. 2014 Feb;32(2):70-9. doi: 10.1016/j.urolonc.2013.01.005. Epub 2013 Mar 15.

PMID:
23506965
8.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
9.

[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

Ouzaid I, Ravery V, Pouessel D, Culine S.

Prog Urol. 2013 Jan;23(1):1-7. doi: 10.1016/j.purol.2012.07.007. Epub 2012 Aug 13. Review. French.

PMID:
23287477
10.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
11.

Metastatic castration-resistant prostate cancer: time for innovation.

Tucci M, Scagliotti GV, Vignani F.

Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.

PMID:
25572785
12.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
13.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Review.

14.

[The treatment of castration-resistant prostate cancer].

Petrányi Á.

Magy Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3. Review. Hungarian.

15.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.

16.

Progress in emerging therapies for advanced prostate cancer.

Oudard S.

Cancer Treat Rev. 2013 May;39(3):275-89. doi: 10.1016/j.ctrv.2012.09.005. Epub 2012 Oct 26. Review.

PMID:
23107383
17.

Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.

Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.

Expert Opin Investig Drugs. 2014 Apr;23(4):469-87. doi: 10.1517/13543784.2014.885950. Epub 2014 Feb 3. Review.

PMID:
24490883
18.

Treatment sequencing in metastatic castrate-resistant prostate cancer.

Sartor O, Gillessen S.

Asian J Androl. 2014 May-Jun;16(3):426-31. doi: 10.4103/1008-682X.126378. Review.

19.

Novel and bone-targeted agents for CRPC.

Fizazi K, Albiges L, Massard C, Escudier B, Loriot Y.

Ann Oncol. 2012 Sep;23 Suppl 10:x264-7.

PMID:
22987974
20.

Potential use of custirsen to treat prostate cancer.

Higano CS.

Onco Targets Ther. 2013 Jun 25;6:785-97. doi: 10.2147/OTT.S33077. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk